High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis

Jing,Zhitao; Li,Long; Wang,Xin; Wang,Minghao; Cai,Ying; Jin,Zi; Zhang,Ye

doi:10.3892/ol.2016.4318

High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis

Authors:
- Zhitao Jing
- Long Li
- Xin Wang
- Minghao Wang
- Ying Cai
- Zi Jin
- Ye Zhang
View Affiliations

Affiliations: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: March 9, 2016 https://doi.org/10.3892/ol.2016.4318
Pages: 2787-2791
Copyright: © Jing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Casitas B-lineage lymphoma (c-Cbl) expression has been linked to the development of several types of cancer. However, no studies on the association of c-Cbl and glioma have been published thus far. The present study examined glioma samples obtained from 136 patients treated at The First Hospital of China Medical University (Shenyang, China) from January 2007 to December 2009, and the expression levels of c‑Cbl in the samples were evaluated by reverse transcription‑quantitative polymerase chain reaction, immunohistochemistry and western blotting. Kaplan‑Meier survival curves were generated and subjected to Cox regression analysis. The messenger RNA and protein levels of c‑Cbl were observed to be upregulated in high‑grade glioma, compared with low‑grade glioma. A multivariate analysis revealed that the protein levels of c‑Cbl were independently associated with overall survival [hazard ratio (HR)=4.923, 95% confidence interval (CI)=3.163‑7.662; P<0.001]. Furthermore, the grade of the glioma (according to the World Health Organization criteria) was observed to be independent prognostic factors for progression‑free survival and overall survival time (HR=8.842, 95% CI=7.827‑9.989; P<0.001, and HR=10.247, 95% CI=9.009‑11.655; P<0.001, respectively). Kaplan‑Meier analysis and log‑rank test indicated that high protein expression levels of c‑Cbl were significantly associated with overall and progression‑free survival (P<0.001). To the best of our knowledge, these results provide the first evidence that the overexpression of c-Cbl is correlated with advanced clinicopathological features and poor prognosis in patients with glioma.

View Figures

View References

1	Ma R, de Pennington N, Hofer M, Blesing C and Stacey R: Diagnostic and prognostic markers in gliomas - an update. Br J Neurosurg. 27:311–315. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hentschel SJ and Lang FF: Current surgical management of glioblastoma. Cancer J. 9:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
3	Diamond EL, Corner GW, De Rosa A, Breitbart W and Applebaum AJ: Prognostic awareness and communication of prognostic information in malignant glioma: A systematic review. J Neurooncol. 119:227–234. 2014. View Article : Google Scholar : PubMed/NCBI
4	Clarke J, Butowski N and Chang S: Recent advances in therapy for glioblastoma. Arch Neurol. 67:279–283. 2010. View Article : Google Scholar : PubMed/NCBI
5	Andoniou CE, Thien CB and Langdon WY: Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J. 13:4515–4523. 1994.PubMed/NCBI
6	Thien CB and Langdon WY: Cbl: Many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol. 2:294–307. 2001. View Article : Google Scholar : PubMed/NCBI
7	Di Fiore PP and De Camilli P: Endocytosis and signaling. An inseparable partnership. Cell. 106:1–4. 2001. View Article : Google Scholar : PubMed/NCBI
8	Joazeiro CA and Hunter T: Biochemistry. Ubiquitination - more than two to tango. Science. 289:2061–2062. 2000. View Article : Google Scholar : PubMed/NCBI
9	Waterman H and Yarden Y: Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490:142–152. 2001. View Article : Google Scholar : PubMed/NCBI
10	Mohapatra B, Ahmad G, Nadeau S, Zutshi N, An W, Scheffe S, Dong L, Feng D, Goetz B, Arya P, et al: Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta. 1833:122–139. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N and Yasui W: Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch. 444:324–331. 2004. View Article : Google Scholar : PubMed/NCBI
12	Cristóbal I, Manso R, Rincón R, Caramés C, Madoz-Gúrpide J, Rojo F and García-Foncillas J: Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. Int J Colorectal Dis. 29:6412014. View Article : Google Scholar : PubMed/NCBI
13	Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, et al: TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer. 99:1849–1858. 2008. View Article : Google Scholar : PubMed/NCBI
14	Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, et al: CBL is frequently altered in lung cancers: Its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 5:e89722010.Hsu HH [added]. View Article : Google Scholar : PubMed/NCBI
15	Shibuya N, Inoue K, Tanaka G, Akimoto K and Kubota K: Augmented pentose phosphate pathway plays critical roles in colorectal carcinomas. Oncology. 88:309–319. 2015. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, et al: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 27:6109–6116. 2009. View Article : Google Scholar : PubMed/NCBI
18	Nam JM, Onodera Y, Mazaki Y, Miyoshi H, Hashimoto S and Sabe H: CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery. EMBO J. 26:647–656. 2007. View Article : Google Scholar : PubMed/NCBI
19	Chiusaroli R, Sanjay A, Henriksen K, Engsig MT, Horne WC, Gu H and Baron R: Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol. 261:537–547. 2003. View Article : Google Scholar : PubMed/NCBI
20	Caveggion E, Continolo S, Pixley FJ, Stanley ER, Bowtell DD, Lowell CA and Berton G: Expression and tyrosine phosphorylation of Cbl regulates macrophage chemokinetic and chemotactic movement. J Cell Physiol. 195:276–289. 2003. View Article : Google Scholar : PubMed/NCBI
21	Lee H and Tsygankov AY: c-Cbl regulates glioma invasion through matrix metalloproteinase 2. J Cell Biochem. 111:1169–1178. 2010. View Article : Google Scholar : PubMed/NCBI